During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback